Primary systemic chemotherapy of invasive lobular carcinoma of the breast
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The benefit of chemotherapy for invasive lobular carcinoma (ILC), a distinct breast cancer subtype, remains unclear due to insufficient evidence. Further research in dedicated clinical trials is essential for optimal treatment strategies.
Area Of Science
- Oncology
- Breast Cancer Research
Background
- Invasive lobular carcinoma (ILC) is the second most common breast cancer, with increasing incidence and unique characteristics.
- ILC typically presents as oestrogen receptor-positive and lower grade compared to invasive ductal carcinoma.
- Current chemotherapy guidelines for ILC are based on invasive ductal carcinoma criteria, despite ILC's distinct nature.
Purpose Of The Study
- To evaluate the current evidence supporting the use of neoadjuvant and adjuvant chemotherapy in invasive lobular carcinoma.
- To highlight the lack of specific data for ILC treatment efficacy.
Main Methods
- Review of randomized controlled trials investigating neoadjuvant and adjuvant chemotherapy.
- Analysis of existing literature to assess chemotherapy benefit in ILC patients.
Main Results
- Insufficient evidence exists to either support or withhold chemotherapy for invasive lobular carcinoma.
- The overall benefit of systemic chemotherapy in ILC patients is currently undefined.
Conclusions
- Invasive lobular carcinoma requires separate investigation in prospective clinical trials.
- Defining optimal treatment and prevention strategies for ILC necessitates dedicated research.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...